Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation.

ABSTRACT:

Objectives

Therapeutic drug monitoring of infliximab improves treatment outcomes, but available assays to monitor infliximab lack speed to implement treatment algorithms immediately. Our aim is to validate a rapid, lateral flow-based assay (LFA) for quantitative determination of infliximab and to assess thresholds associated with mucosal healing in patients with ulcerative colitis.

Methods

Samples (n=190) from 29 anti-tumor necrosis factor naive patients with ulcerative colitis starting infliximab induction therapy between June 2010 and February 2012 were prospectively collected. All patients had a Mayo endoscopic sub-score ≥2 at baseline. Mucosal healing (MH), defined as a Mayo endoscopic sub-score ≤1, was evaluated at week 10-14. Infliximab trough concentrations (TC) were

SUBMITTER: Van Stappen T 

PROVIDER: S-EPMC5288585 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature